Effects of omega-3 administration on homocysteine serum concentration in renal transplant recipient
-
AmirHooshang Mohammadpour
,
Seyed Adel Moallem
,
Maryam Bafandegan
,
Jamal Shamsara
,
Fatemeh Nazemian
Abstract
Background: It has been shown that serum total homocysteine (HC) is a risk factor for vascular disease which characterizes endothelial damage in the general and in the End-Stage Renal Disease (ESRD) population as well. Whether n-3 polyunsaturated fatty acids decrease homocysteine (Hcy) level has been a subject of controversy.
Methods: Renal transplant patients were randomized in 2 groups and received 6 months of dietary supplementation with 6 g/day of Fish oil or placebo. Homocysteine level and total cholesterol level were measured.
Results: In 40 renal transplant recipients, increase in homocysteine level was greater after Fish oil administration but not significantly, total cholesterol was decreased significantly.
Conclusion: Based on these data omega3 fatty acids supplementation doesn’t decrease serum homocysteine in renal transplant recipients but decreases total cholesterol level.
Ostovan MA, Fazelzadeh A, Mehdizadeh AR, Razmkon A, Malek-Hosseini SA. How to decrease cardiovascular mortality in renal transplant recipients. Transplant Proc. 2006; 38 (9): 2887-92.
Chavalitdhamrong D, Danovitch GM, Bunnapradist S. Is there a reversal of reverse epidemiology in renal transplant recipients? Semin Dial. 2007; 20 (6): 544-8.
Laures AS, Gomez E, Baltar J, Alvarez-Grande J. Risk factors for cardiovascular disease during the first 2 years after renal transplantation. Transplant Proc. 2005; 37 (9): 3778-81.
Wierzbicki AS. Homocysteine and cardiovascular disease: a review of the evidence. Diab Vasc Dis Res. 2007; 4 (2): 143-50.
Marcucci R, Zanazzi M, Bertoni E, Rosati A, Fedi S, Lenti M, et al. Homocysteine-lowering therapy and carotid intima-media thickness in renal transplant recipients. Transplant Proc. 2005: 37 (6):2491-2.
Kothekar MA. Homocysteine in cardiovascular disease: a culprit or an innocent bystander? Indian J Med Sci. 2007; 61 (6): 361-71.
Diaz JM, Sainz Z, Gich I, Guirado LL, Puig T, Oliver A, et al. Factors involved in baseline hyperhomocysteinemia in renal transplantation. Transplant Proc. 2005; 37 (9): 3799-801.
Manrique J, Diaz A, Gavira JJ, Hernandez A, Pujante D, Errasti, P. Preliminary results of the effect of treatment of hyperhomocysteinemia and its relationship with inflammation, coagulation status, and endothelial function after renal transplantation. Transplant Proc. 2005: 37 (9): 3782-4.
Winkelmayer WC, Kramar R, Curhan GC, Chandraker A, Endler G, Fodinger M, et al. Fasting plasma total homocysteine levels and mortality and allograft loss in kidney transplant recipients: a prospective study. J Am Soc Nephrol. 2005; 16 (1): 255-60.
Piovesan F, Veronese FJ, Santos AF, Pozza R, Sarturi PS, Tognon A, et al. Serum homocysteine levels in renal transplant recipients with and without hypercholesterolemia. Arq Bras Cardiol. 2007; 89 (3): 154-9, 170-5.
Xu T, Zhang XW, Qu XK, Ye HY, Huang XB, Zhang XP, et al. Treatment of hyperhomocysteinemia and endothelial dysfunction in renal transplant recipients with B vitamins in the Chinese population. J Urol. 2008; 179 (3): 1190-4.
Castro R, Queiros J, Fonseca I, Pimentel JP, Henriques AC, Sarmento AM, et al. Therapy of post-renal transplantation hyperlipidaemia: Comparative study with simvastatin and fish oil. Nephrol Dial Transplant. 1997; 12 (10): 2140-3.
Grekas D, Kassimatis E, Makedou A, Bacharaki D, Bamichas G, Tourkantonis A. Combined treatment with low-dose pravastatin and fish oil in post-renal transplantation dislipidemia. Nephron. 2001; 88 (4): 329-33.
Zeman M, Zak A, Vecka M, Tvrzicka E, Pisarikova A, Stankova B. [Effect of n-3 polyunsaturated fatty acids on plasma lipid, LDL lipoperoxidation, homocysteine and inflammation indicators in diabetic dyslipidemia treated with statin + fibrate combination]. Cas Lek Cesk. 2005; 144 (11): 737-41.
Grundt H, Nilsen DW, Mansoor MA, Hetland O, Nordoy A. Reduction in homocysteine by n-3 polyunsaturated fatty acids after 1 year in a randomised double-blind study following an acute myocardial infarction: no effect on endothelial adhesion properties. Pathophysiol Haemost Thromb. 2003; 33 (2): 88-95.
Olszewski AJ, McCully KS. Fish oil decreases serum homocysteine in hyperlipemic men. Coron Artery Dis. 1993; 4 (1): 53-60.
Holdt B, Korten G, Knippel M, Lehmann JK, Claus R, Holtz M, et al. Increased serum level of total homocysteine in CAPD patients despite fish oil therapy. Perit Dial Int. 1996; 16 Suppl 1): S246-9.)
Grundt H, Nilsen DW, Hetland O, Mansoor MA, Aarsland T, Woie L. Atherothrombogenic risk modulation by n-3 fatty acids was not associated with changes in homocysteine in subjects with combined hyperlipidaemia. Thromb Haemost. 1999; 81 (4): 561-5.
Beavers KM, Beavers DP, Bowden RG, Wilson RL, Gentile M. Omega-3 fatty acid supplementation and total homocysteine levels in end-stage renal disease patients. Nephrology (Carlton). 2008; 13 (4): 284-8.
Hernandez D, Guerra R, Milena A, Torres A, Garcia S, Garcia C, et al. Dietary fish oil does not influence acute rejection rate and graft survival after renal transplantation: a randomized placebo-controlled study. Nephrol Dial Transplant. 2002; 17 (5): 897-904.
Piolot A, Blache D, Boulet L, Fortin LJ, Dubreuil D, Marcoux C, et al. Effect of fish oil on LDL oxidation and plasma homocysteine concentrations in health. J Lab Clin Med. 2003; 141 (1): 41-9.
| Files | ||
| Issue | Vol 1, No 1 (Winter 2013) | |
| Section | Original Article(s) | |
| Keywords | ||
| Homocysteine Renal Transplantation Fish oils | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
